Crossmark

Downplaying toxicities in cancer drug trials is not acceptable

Crossref DOI link: https://doi.org/10.1038/s41591-026-04463-x

Published Online: 2026-06-01

Published Print: 2026-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gyawali, Bishal https://orcid.org/0000-0001-7444-8594
License Information

Text and Data Mining valid from 2026-06-01

Version of Record valid from 2026-06-01
More Information

Article History

First Online: 1 June 2026

Ethics

Competing interests: The author declares no competing interests.